

**IRTU International workshop: Malignant and nonmalignant
hematologic disorder and allo-HSCT approaches
April 26-27, 2025**

irtu.online

Day 1. Satellite symposium

TBD

Day 2: Malignant and nonmalignant hematologic disorder and allo-HSCT
approaches

Key sessions (Virtual Hall 1/2)

Health organization section Chairmans: Amir Ali Hamidieh, Elena Parovichnikova, Fevzi Altuntaş, Miralisher Islamov	
09:00-09:12	I - Health organization: Iran (Amir Ali Hamidieh)
09:12-09:15	Q&A Session
09:15-09:27	R - Health organization:Russia (Elena Parovichnikova)
09:27-09:30	Q&A Session
09:30-09:42	T - Health organization:Türkiye (Fevzi Altuntaş)
09:42-09:45	Q&A Session
09:45-09:57	U - Health organization:Uzbekistan (Miralisher Islamov)
09:57-10:00	Q&A Session
Infections - Life-threatening infections: KPE, Mycosis and etc. Chairmans: Gülşen İskender, Hamid Eshaghi, Galina Klyasova, Sardorbek Mukhammadiev	
15:15-15:27	Infections due to carbapenemase- producing Enterobacteriaceae in hematologic patients - Galina Klyasova (Russia)
15:27-15:30	Q&A Session

15:30-15:42	Infections in allo-HSCT patients in Uzbekistan - Sardorbek Mukhammadiev (Uzbekistan)
15:42-15:45	Q&A Session
15:45-15:57	Fungal infection in routine practice in Türkiye -Gülşen İskender (Türkiye)
15:57-16:00	Q&A Session
16:00-16:12	Diagnosis and management of CMV infection in recipients of hematopoietic stem cell transplantation - Hamid Eshaghi (Iran)
16:12-16:15	Q&A Session

Malignant and nonmalignant hematologic disorder (Virtual Hall 1)

Major Thalassemia/Sickle Cell Anemia/AIHA Chairmans: Dila Suleymanova, Gennadyi Galstyan, Hadi Mottaghipisheh, Gül İlhan	
10:00-10:12	TTP in Russia – Gennadyi Galstyan (Russia)
10:12-10:15	Q&A Session
10:15-10:27	Thalassemia in Uzbekistan - Dila Suleymanova (Uzbekistan)
10:27-10:30	Q&A Session
10:30-10:42	Approaches to the treatment of thalassemia in Turkey -Gül İlhan (Türkiye)
10:42-10:45	Q&A Session
10:45-10:57	Novel therapy for Sickle Cell Anemia - Hadi Mottaghipisheh (Iran)
10:57-11:00	Q&A Session
Acute leukemia/MDS Chairmans: Elena Parovichnikova, Sayeh Parkhideh, Ildor Ishakov, Sinem Namdaroğlu, Aziz Eghbali	

11:00-11:12	Clinical trials in patients with acute leukemia in Russia - Elena Parovichnikova (Russia)
11:12-11:15	Q&A Session
11:15-11:27	AML in pregnancy - Ildor Ishakov (Uzbekistan)
11:27-11:30	Q&A Session
11:30-11:42	Treatment of AML with modern drugs: own experience Sinem Namdaroğlu (Türkiye)
11:42-11:45	Q&A Session
11:45-11:57	Immunotherapy in pediatric relaps/refractory Acute Lymphoblastic Leukemia - Aziz Eghbali (Iran)
11:57-12:00	Q&A Session
12:00-12:12	Novel therapeutic approaches for myelodysplastic syndromes - Sayeh Parkhideh (Iran)
12:12-12:15	Q&A Session
Multiple Myeloma Chairmans: Fevzi Altuntaş, Larisa Mendeleeva, Farzaneh Ashrafi, Gulchihra Kuzieva, Maxim Solovyev	
12:15-12:27	Primary plasma cell leukemia : diagnosis and treatment - Maxim Solovyev(Russia)
12:27-12:30	Q&A Session
12:30-12:42	New approaches in multiple myeloma - Gulchihra Kuzieva (Uzbekistan)
12:42-12:45	Q&A Session
12:45-12:57	Clinical trials in Republic of Türkiye - Fevzi Altuntaş (Türkiye)
12:57-13:00	Q&A Session
13:00-13:12	Monoclonal Gammopathies: More Than Just a Lab Result - Farzaneh Ashrafi (Iran)
13:12-13:15	Q&A Session
Hodgkin's lymphoma/non-Hodgkin lymphoma/CLL	

Chairmans: Evgeniy Zvonkov, Düzgün Özatlı, Maryam Barkhordar, Kamoliddin Olimjonov	
13:15-13:27	Evgeniy Zvonkov (Russia)
13:27-13:30	Q&A Session
13:30-13:42	Auto-HSCT for lymphoma treatment - Kamoliddin Olimjonov (Uzbekistan)
13:42-13:45	Q&A Session
13:45-13:57	Approaches to the treatment of lymphomas: own data- Düzgün Özatlı (Turkiye)
13:57-14:00	Q&A Session
14:00-14:12	Immune cell therapy for lymphoma - Maryam Barkhordar (Iran)
14:12-14:15	Q&A Session
CML - Algorithms for managing patients with CML in different countries Chairmans: Anna Turkina, Mehmet Sinan Dal, Khamida Kazakbaeva, Hossein Ghasemi Moghaddam	
14:15-14:27	Management options for chronic myeloid leukemia patients with optimal response to therapy - Ekaterina Chelysheva (Russia)
14:27-14:30	Q&A Session
14:30-14:42	CML in Uzbekistan - Khamida Kazakbaeva (Uzbekistan)
14:42-14:45	Q&A Session
14:45-14:57	Algorithms for managing patients with CML in Türkiye -Mehmet Sinan Dal (Turkiye)
14:57-15:00	Q&A Session
15:00-15:12	Chronic myeloid leukemia management in blast crisis - Hossein Ghasemi Moghaddam (Iran)
15:12-15:15	Q&A Session
Hemophilia: Today and tomorrow Chairmans: Aziza Makhmudova, Cengiz Demir, Nadezhda Zozulya, Babak Abdolkarimi	

16:15-16:27	Approaches to the treatment of hemophilia in Uzbekistan - Aziza Makhmudova (Uzbekistan)
16:27-16:30	Q&A Session
16:30-16:42	Nadezhda Zozulya (Russia) - The possibilities of hemophilia treatment in the Russian Federation
16:42-16:45	Q&A Session
16:45-16:57	Approaches to the treatment of hemophilia in Turkey -Cengiz Demir (Turkiye)
16:57-17:00	Q&A Session
17:00-17:12	Novel approaches in hemophilia treatment - Babak Abdolkarimi (Iran)
17:12-17:15	Q&A Session

Transplant approaches (Virtual Hall 2)

HSCT for malignant hematologic disorders Chairmans: Mikhail Drokov, Abdurakhmon Kayumov, Fevzi Altuntaş, Abbas Hajifathali	
10:00-10:12	The structure of adult allo-HSCT care in Russia Mikhail Drokov (Russia)
10:12-10:15	Q&A Session
10:15-10:27	Transplant activity in Uzbekistan - Abdurakhmon Kayumov (Uzbekistan)
10:27-10:30	Q&A Session
10:30-10:42	Transplant activity in Türkiye - Fevzi Altuntaş (Türkiye)
10:42-10:45	Q&A Session
10:45-10:57	Manipulation of HSC before HSCT in hematologic malignancy - Abbas Hajifathali (Iran)
10:57-11:00	Q&A Session
Aquarial Aplastic Anemia/Congenital Bone Marrow Failure and HSCT for non-malignant hematologic disorders	

Chairmans: Amir Ali Hamidieh, Mehmet Bakırtaş, Vahid Falahati , Elena Mikhailova, Zalina Fidarova, Inna Berger	
11:00-11:12	Haploidentical transplantation as first-line therapy in patients with aplastic anemia with severe infections - Zalina Fidarova (Russia)
11:12-11:15	Q&A Session
11:15-11:27	Approach to AA treatment in Uzbekistan - Inna Berger (Uzbekistan)
11:27-11:30	Q&A Session
11:30-11:42	The structure of non-malignant hematologic disorder and approaches to their treatment in Türkiye - Mehmet Bakırtaş (Türkiye)
11:42-11:45	Q&A Session
11:45-11:57	Halpoidential hematopoetic stem cell transplantation for acquired severe aplastic anemia - Vahid Falahati (Iran)
11:57-12:00	Q&A Session
12:00-12:12	Allogeneic hematopoietic stem cell transplantation for congenital bone marrow failures - Amir Ali Hamidieh (Iran)
12:12-12:15	Q&A Session
GVHD prophylaxis/Graft failure Chairmans: Maryam Behfar, Burhan Turgut, Ozoda Achilova, Natalia Popova	
12:15-12:27	Natalia Popova (Russia)
12:27-12:30	Q&A Session
12:30-12:42	Low-dose PT-Cy in Uzbekistan - Ozoda Achilova (Uzbekistan)
12:42-12:45	Q&A Session
12:45-12:57	GVHD prophylaxis approach in allo-HSCT in Türkiye- Burhan Turgut (Türkiye)

12:57-13:00	Q&A Session
13:00-13:12	The impact of anti-HLA antibodies on graft failure in HSCT- Maryam Behfar (Iran)
13:12-13:15	Q&A Session
acute GVHD/chronic GVHD Chairmans: Leyla Jafari, Mahmut Yeral, Vera Vasiliyeva, Saidburkhon Asilov	
13:15-13:27	The comparison of effectiveness and outcome of using cryopreserved photopheresis product vs fresh in pediatric patients with SR-GVHD - Leyla Jafari (Iran)
13:27-13:30	Q&A Session
13:30-13:42	Therapy for steroid-refractory acute and chronic graft-versus-host disease using cryopreserved mononuclear cells subjected to extracorporeal phototherapy– Vera Vasilyeva (Russia)
13:42-13:45	Q&A Session
13:45-13:57	Approach to SR-GVHD: ruxolitinib vs ECP - Mahmut Yeral (Turkiye)
13:57-14:00	Q&A Session
14:00-14:12	Structure of acute and chronic GVHD in Uzbekistan - Saidburkhon Asilov (Uzbekistan)
14:12-14:15	Q&A Session
Intensive care in allo-HSCT Chairmans: Gennadiy Galstyan, Zeynab Najafi, İlhami Berber, Dono Julamanova	
14:15-14:27	Gennadiy Galstyan/Antonina Shekina (Russia)
14:27-14:30	Q&A Session
14:30-14:42	Intensive care in hematological patients -Dono Julamanova (Uzbekistan)
14:42-14:45	Q&A Session

14:45-14:57	TMA in allo-HSCT -İlhami Berber (Türkiye)
14:57-15:00	Q&A Session
15:00-15:12	Post HSCT pulmonary critical care issues in pediatric - Zeynab Najafi (Iran)
15:12-15:15	Q&A Session
Cell therapy Chairmans: Abdurakhmon Kayumov, Hamid Farajifard, Tuğçe Yeneroglu, Olga Aleshina	
16:15-16:27	Olga Aleshina (Russia)
16:27-16:30	Q&A Session
16:30-16:42	Cell therapy needs and legislation in the Republic of Uzbekistan - Abdurakhmon Kayumov (Uzbekistan)
16:42-16:45	Q&A Session
16:45-16:57	CAR-T cells and cell therapy in Türkiye - Tuğçe Yeneroglu (Türkiye)
16:57-17:00	Q&A Session
17:00-17:12	CMV specific T-cell for treatment of cmv resistance infection during HSCT - Hamid Farajifard (Iran)
17:12-17:15	Q&A Session